Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor.
about
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation TherapyClinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indicationsClinical pharmacokinetic and pharmacodynamic profile of rivaroxabanPharmacology of anticoagulants used in the treatment of venous thromboembolismPharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolismLiver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting systemDirect Oral Anticoagulants in Cirrhosis.Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation.Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants.New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplastyRisk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin.Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.New oral anticoagulants and the cancer patient.Rivaroxaban and hemostasis in emergency care.Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk.Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.Novel oral anticoagulants: clinical pharmacology, indications and practical considerations.Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation.Rivaroxaban for the treatment and prevention of thromboembolic disease.Dosing of Target-Specific Oral Anticoagulants in Special Populations.Clinical development of rivaroxaban: emerging new clinical evidences?Dosing of rivaroxaban by indication: getting the right dose for the patient.Drug-drug interactions of non-vitamin K oral anticoagulants.Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice.Direct oral anticoagulant considerations in solid organ transplantation: A review.Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis.An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics.Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring.Erratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism.Treating thrombosis in cirrhosis patients with new oral agents: ready or not?Portal vein thrombosis occurrence in a cirrhotic patient during treatment with rivaroxaban.Portal vein thrombosis in patients with cirrhosis: underdiagnosis and undertreatment?Newer Oral Anticoagulants in the Treatment of Acute Portal Vein Thrombosis in Patients with and without Cirrhosis.Interindividual variability in dabigatran and rivaroxaban exposure: contribution ofABCB1genetic polymorphisms and interaction with clarithromycinTiming of Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: An Italian Internist's Perspective
P2860
Q26766303-A7DBF183-068A-4760-BFA0-2EEDA6AE8D4BQ26828817-BC710BAE-11B1-43B4-94F9-006A493A4755Q26864411-65ECC2F1-7E1C-4306-B163-661E875E4A72Q28078967-ACB184C7-DD51-417D-82B0-4646AEE8BA3DQ28087447-15ECC85B-7934-42B3-A2D1-1529CF0BD4F9Q28257188-4074328B-B23C-45FD-9EB8-3CE269E2886BQ30277086-3D05DF65-D771-4ECB-9E4B-9DCD56667589Q30277819-A4B2A23D-E2A0-4E75-B7DE-F06421C867E6Q33854667-363967BC-E7DB-41BB-8E8F-DE4D10CB21F2Q33891915-C826273F-3594-4DA7-83F4-10BCA8389E84Q36531658-A537B23A-1F00-4946-8C4A-352EEE9DD444Q37470692-A7EC4C7F-5621-4FE4-9815-28CD083F0B1BQ37519054-AA069DB3-E75D-4D92-80A8-631848A34A48Q37631564-F67CEC33-D38C-4E23-89E1-AC17CFA2FC9CQ37641965-ACF1161B-4B0A-40B9-B168-19A41F7E1FE6Q38079779-87CF0B42-28AC-4E9E-8E31-F804C1609B8EQ38101845-03F7A870-6F27-49A3-AF0A-F5E28508D961Q38175211-C8A93AB6-7C4F-4F30-8AA5-36F225EFA97BQ38178891-9551B4BC-7ED3-497E-84D9-5B9101C1F7DAQ38221812-5A0CB130-18BA-4DC8-A21A-DAA4192FB2B7Q38253565-DA2D3BD8-A972-47DC-94FC-9B7ADAF7C6E5Q38386998-42907E49-B586-49FA-B3E4-576D970E1ED3Q38522824-0A3CF342-12D9-480C-A54A-9951E9267E01Q38535649-5B0683E7-4306-49F3-BEC9-03EE797CF8B3Q38537785-2C6366DB-C7CA-4799-B32B-4B3052BBA66EQ38578543-16D600E1-9D5E-4DB5-A4D2-57C1653373F4Q38830358-915EBE84-C9A2-4517-8053-A501AD4EA5A6Q38953655-A335888F-6D0E-4A2B-A342-B05DFAF23449Q39012313-B333C052-703C-4FD1-9220-6DBD746371A6Q39453858-64A1A147-F303-4FB9-82F4-3935D23CAAF0Q40410373-6B15AF3E-92DE-45F9-8873-C8325DCBDF09Q40901259-794143AF-767A-4BFD-8CE0-BE582A08044AQ42188952-462509ED-D101-40FA-B350-4DC28F6B04ACQ42387444-B022F2A8-9120-4C47-AED3-BD3D036BF27EQ44998149-4B0D56C3-8C5C-41B6-9345-F3C375A1741FQ48154202-1F3EF740-F3D4-4E1B-9721-8BCF2B6CD9A3Q53783646-27BEFDB5-AAC9-4E1D-B2A1-4A38FBE77316Q55442446-54698B35-056E-4A1E-B55E-ADBA6C82D715Q57314038-CB4EFABE-F412-4882-AF63-B1868923A227Q57652415-AC63AF3F-CCC8-4926-8164-259A07E6F1FE
P2860
Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Effect of hepatic impairment o ...... l, direct Factor Xa inhibitor.
@en
type
label
Effect of hepatic impairment o ...... l, direct Factor Xa inhibitor.
@en
prefLabel
Effect of hepatic impairment o ...... l, direct Factor Xa inhibitor.
@en
P2093
P2860
P356
P1476
Effect of hepatic impairment o ...... l, direct Factor Xa inhibitor.
@en
P2093
Abir Alatrach
Angelika Roth
Atef Halabi
Dagmar Kubitza
Holger Hinrichsen
Michael Becka
Wolfgang Mueck
P2860
P356
10.1111/BCP.12054
P407
P577
2013-07-01T00:00:00Z